Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
17. Dezember 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
29. August 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Immuneering Recognizes Melanoma Awareness Month
06. Mai 2024 16:30 ET
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03. April 2024 16:05 ET
|
Immuneering Corporation
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
27. März 2024 08:00 ET
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
12. Dezember 2023 08:00 ET
|
Immuneering Corporation
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
20. November 2023 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients...
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
09. November 2023 16:05 ET
|
Immuneering Corporation
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering’s recommendation for a Phase 2 dose expected in early 2024 - - Expanded clinical development...
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
12. Oktober 2023 16:05 ET
|
Immuneering Corporation
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven...
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04. Oktober 2023 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...